The U.S. Securities and Exchange Commission (SEC) has upheld Nasdaq’s decision to delist Shineco Inc., a Chinese biotech firm, due to multiple violations of listing requirements. The SEC rejected Shineco’s appeal, which argued that the Nasdaq hearing panel acted too swiftly and overlooked plans for new operations.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.law360.com/articles/2515544/sec-won-t-lift-trading-suspension-on-chinese-biotech-firm
